Abtis Co Ltd

Abtis Co Ltd (often referred to as AbTis) is a South Korean biotechnology company founded in 2016. Headquartered in Yongin-si, Gyeonggi-do, Republic of Korea, the company was acquired by Dong-A ST in 2023 and operates as an operating subsidiary. AbTis has approximately 20 employees.

AbTis specializes in the development of antibody-drug conjugates (ADCs) using its proprietary AbClick® platform technology. This platform enables site-selective conjugation of therapeutic payloads to antibodies without requiring antibody modification, aiming to enhance the safety and efficacy of ADC therapies. Their technology is applicable to various bioconjugate treatments, including ADCs, DACs, AOCs, ISACs, and ARCs. The company's pipeline includes candidates targeting solid tumors like gastric and breast cancers.

In terms of patent litigation, Abtis Co Ltd appears to be an operating company defending against intellectual property challenges. The company has a total of 29 patents. According to the provided data, Abtis Co Ltd has been involved in one tracked case, appearing solely as a defendant. This case, Ajinomoto Co., Inc. v. Abtis Co Ltd, was heard before the Patent Trial and Appeal Board (PTAB), indicating a post-grant challenge to a patent.

The specific case, Ajinomoto Co., Inc. v. Abtis Co Ltd, highlights a potential dispute related to their core technology, as Ajinomoto also possesses a site-specific binding technology for payloads called 'AjiCAP'. AbTis's AbClick® platform is specifically noted for its ability to bind payloads to the lysine on the Fc site of antibodies.